We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


XDx Selects Ingenuity Systems for Pathways Solution

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "XDx Selects Ingenuity Systems for Pathways Solution"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Ingenuity Systems has announced that XDx has licensed Ingenuity’s flagship solution IPA 5.0. Ingenuity Systems was selected by XDx after a comprehensive evaluation of several pathway analysis products.

XDx is a molecular diagnostics company based in Brisbane, California. The company has developed a new method for noninvasively monitoring the immune system by measuring gene expression in a patient’s peripheral blood. The technology can offer the potential to improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases.

"We chose IPA because it best meets our objective to identify and understand biomarkers associated with immune-mediated diseases,” commented Dr. Tod Klingler, VP of Informatics at XDx.

“IPA provides us with access to its extensive knowledge base of gene function information assembled from the scientific literature through easy-to-use tools that our researchers can use to rapidly evaluate candidate biomarkers. Specifically, IPA allows us to make sense of our gene expression data in the context of known immune system interactions and pathways.”